< Back to previous page
Researcher
Steven Joniau
- Disciplines:Urology and nephrology
Affiliations
- Urogenital, Abdominal and Plastic Surgery (Division)
Member
From1 Jan 2019 → Today - Woman and Child (Division)
Member
From1 Apr 2013 → 31 Dec 2018
Projects
1 - 10 of 19
- Improvement of therapeutic management in patients with high-risk and oligorecurrent prostate cancerFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development of treatment intensification strategies for high-risk prostate cancer based on clinicopathological and molecular modeling, with the aim of delivering precision medicine to the individual patient.From1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The role of stromal components in urothelial cancerFrom4 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- New insights in the genomic architecture and treatment of high risk and oligometastatic prostate cancerFrom10 Sep 2021 → 30 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE)From24 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Classical and non-classical actions of androgens and their receptorFrom1 Oct 2019 → 30 Sep 2023Funding: IOF - technology concept exploration, BOF - projects
- Fellowship: Optimization patient treatment pathway by combining genotypic and phenotypic data.From17 Dec 2018 → 16 Dec 2019Funding: Private funding of national origin - undefined
- Novel insights in the definition and treatment of high risk and oligometastatic prostate cancerFrom1 Oct 2018 → 18 Nov 2022Funding: FWO fellowships
- Traveling the prostate cancer timeline in chase of treatment paradigms Can we cure the incurable?From1 Aug 2017 → 1 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- Towards a better stratification of intermediate- and high-risk non-muscle-invasive bladder cancer patientsFrom1 Sep 2016 → 1 Sep 2020Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
41 - 50 of 541
- Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis(2022)
Authors: Steven Joniau
Pages: 82 - 96 - Optimizing treatment and follow-up of patients with bladder cancer: risk stratification and biomarkers(2022)
Authors: Tim Muilwijk, Steven Joniau, Maarten Albersen, Thomas Gevaert
- Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy(2022)
Authors: Gaëtan Devos, Steven Joniau, Hendrik Van Poppel
Pages: 285 - 295 - External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer(2022)
Authors: Steven Joniau
Pages: 1772 - + - Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma(2022)
Authors: Eduard Roussel, Lisa Kinget, Bram Boeckx, Steven Joniau, Diether Lambrechts, Maarten Albersen, Benoit Beuselinck
Pages: 54 - 57 - THE RISK OF RECURRENCE IN CN1 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY VARIES ACCORDING TO THE TYPE PREOPERATIVE STAGING. A COMPARISON BETWEEN 68GA-PSMA-PET VERSUS CONVENTIONAL IMAGING IN A LARGE, MULTI-INSTITUTIONAL STUDY(2022)
Authors: Gaëtan Devos, Steven Joniau
Pages: E882 - E883 - Clinical and preclinical studies of modulators of high-risk prostate cancer with metastatic potential(2022)
Authors: Lisa Moris, Frank Claessens, Steven Joniau
- Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status(2022)
Authors: Frank Claessens, Steven Joniau
- Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer(2022)
Authors: Lisa Moris, Bram Boeckx, Diether Lambrechts, Christine Helsen, Bart Ghesquière, Stefaan Soenen, Elien Smeets, Roy Eerlings, Sarah El Kharraz, Hendrik Van Poppel, et al.
Pages: 527 - 541 - Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study(2022)
Authors: Tim Muilwijk, Steven Joniau
Pages: 491 - 497